In a phase 1b clinical trial called RIDGE-1 (NCT06228924), the safety, tolerability, and efficacy of TN-401 (an AAV-based gene therapy designed to deliver a functional PKP2 gene) are evaluated in adult patients with ARVC caused by PKP2 mutations.196. The gene discussed is PKP2; the disease is arrhythmogenic right ventricular cardiomyopathy.